Cresco Labs (FRA:6CQ) Net Current Asset Value: €-1.44 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:6CQ Cresco Labs Inc FRA:6CQ
43 GF Score
Price €0.63
GF Value €0.88
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Cresco Labs Net Current Asset Value?

Cresco Labs FRA:6CQ -0.32% 43 Net Current Asset Value is €-1.44 as of Mar. 2026. GuruFocus rates FRA:6CQ with a GF Score™ of 43/100 and a GF Value™ of €0.88 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 611 Drug Manufacturers companies, Cresco Labs ranks worse than 163665.96% on this metric.

In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).

Cresco Labs's net current asset value per share for the quarter that ended in Mar. 2026 was €-1.44.

The historical rank and industry rank for Cresco Labs's Net Current Asset Value or its related term are showing as below:

FRA:6CQ's Price-to-Net-Current-Asset-Value is not ranked *
in the Drug Manufacturers industry.
Industry Median: 5.78
* Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.

Cresco Labs  (FRA:6CQ) Net Current Asset Value Explanation

Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."

The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]

Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham’s strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.


Cresco Labs Net Current Asset Value Related Terms


Cresco Labs Net Current Asset Value Historical Data

* Premium members only.

The historical data trend for Cresco Labs's Net Current Asset Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cresco Labs Net Current Asset Value Chart

Cresco Labs Annual Data
Trend Jan16 Jan17 Jan18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Net Current Asset Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.84 -1.98 -1.55 -1.61 -1.42

Cresco Labs Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Net Current Asset Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.55 -1.44 -1.45 -1.42 -1.44

FRA:6CQ vs ZTS, UTHR: Net Current Asset Value Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Cresco Labs's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cresco Labs Price-to-Net-Current-Asset-Value vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cresco Labs's Price-to-Net-Current-Asset-Value distribution charts can be found below:

* The bar in red indicates where Cresco Labs's Price-to-Net-Current-Asset-Value falls into.


FRA:6CQ
43GF Score
Cresco Labs Inc FRA:6CQ
Net Current Asset Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cresco Labs Net Current Asset Value Calculation

Cresco Labs's Net Current Asset Value (NCAV) per share for the fiscal year that ended in Dec. 2025 is calculated as

Net Current Asset Value Per Share(A: Dec. 2025 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(221.419-806.857--75.107-0)/359.533
=-1.42

Cresco Labs's Net Current Asset Value (NCAV) per share for the quarter that ended in Mar. 2026 is calculated as

Net Current Asset Value Per Share(Q: Mar. 2026 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(213.37-825.771--79.421-0)/370.499
=-1.44

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Net Current Asset Value of €-1.44 mean?
Cresco Labs (FRA:6CQ) has a Net Current Asset Value of €-1.44 as of Mar. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Cresco Labs and its competitors. According to the industry distribution chart, Cresco Labs ranks #999999 out of 611 companies in the Drug Manufacturers industry.
Is Cresco Labs' Net Current Asset Value too high?
Cresco Labs' current Net Current Asset Value is €-1.44. Based on the distribution chart, Cresco Labs ranks #999999 out of 611 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Cresco Labs has a GF Score™ of 43/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cresco Labs' Net Current Asset Value compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Cresco Labs ranks #999999 out of 611 companies for Net Current Asset Value. This places Cresco Labs in the lower half of its industry. The industry median Net Current Asset Value is 5.78. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Drug Manufacturers company?
The median Net Current Asset Value among Drug Manufacturers companies is 5.78, based on 611 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Cresco Labs and its competitors. For the Drug Manufacturers industry, the median Net Current Asset Value is 5.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cresco Labs's current Net Current Asset Value is €-1.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cresco Labs stock overvalued right now?
Based on GuruFocus' analysis, Cresco Labs (FRA:6CQ) is currently considered Modestly Undervalued. The stock's GF Value™ is €0.88, compared to a current price of €0.63 — trading 29% below its estimated fair value. The current Net Current Asset Value is €-1.44. Cresco Labs' overall GF Score™ is 43/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Cresco Labs (FRA:6CQ), the current Net Current Asset Value is €-1.44 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cresco Labs (FRA:6CQ) Overvalued in 2026?

Based on GuruFocus' analysis, Cresco Labs stock appears to be undervalued. The current stock price of €0.63 is trading 29% below its estimated GF Value™ of €0.88. GuruFocus considers Cresco Labs to be Modestly Undervalued.

Key valuation signals for FRA:6CQ:

  • Net Current Asset Value: €-1.44
  • GF Value™: €0.88 vs. price of €0.63 (29% below fair value)
  • GF Score™: 43/100 with 5 warning signs

No single metric tells the full story. See the FRA:6CQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Cresco Labs Business Description

Address 600 W. Fulton Street, Suite 800, Chicago, IL, USA, 60661
Cresco Labs Inc is a vertically-integrated multi-state cannabis operator in the United States licensed to cultivate, manufacture, and sell retail and medical cannabis products through Sunnyside, Cresco Lab's national dispensary brand, and others. The company operates in one segment: the cultivation, manufacturing, distribution, and sale of cannabis. The company's brand includes: Cresco, High Supply, FloraCal Farms, Good News, Wonder Wellness Co., Mindy's, and Remedi.
43GF Score

Get the complete analysis for FRA:6CQ

Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.63
Price
€0.88
GF Value